AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04753099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupation-based coaching
Description: Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2).
Study NCT04091425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 IV infusion
Study NCT04091425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 placebo-matching IV infusion
Study NCT03636919 — intervention group
Intervention type: OTHER
Intervention: e-BOOK
Description: Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
Study NCT04184336 — intervention group
Intervention type: OTHER
Intervention: surveillance
Study NCT03019770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Decision Aid
Description: All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
Study NCT02779192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 200mg
Description: Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
Study NCT02779192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 400mg
Description: Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
Study NCT04156412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant test procedure
Description: Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
Study NCT02779192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
Study NCT03360175 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study
Description: No intervention - observational study
Study NCT02641002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90002
Description: Monoclonal Ab to CD47
Study NCT01613378 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study NCT00269581 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational CD-rom
Description: Educational CD-Rom
Study NCT00269581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headstrong CD-rom
Description: Headstrong CD-rom
Study NCT00708708 — intervention group
Intervention type: DRUG
Intervention: etanercept (Enbrel®)
Description: The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT01056640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intel Health Guide
Description: The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
Study NCT01056640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care intervention will include appropriate primary care and specialty office practice visits as required.
Study NCT04396743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with use of prf-high clot and membrane
Description: Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
Study NCT04396743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with use of prf-medium clot and membrane
Description: Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
Study NCT00903019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Problem-Solving Therapy
Description: Six sessions of tele-PST
Study NCT00903019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person PST
Description: Six sessions of in person PST
Study NCT00903019 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Six weekly telephone calls
Study NCT01012388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
Study NCT01691963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)
Description: Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position.
Study NCT04675944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: 200 mg (2 x 100 mg tablets), oral route
Study NCT02291692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral blockade
Description: ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
Study NCT02736292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practices for Healthcare Professionals
Study NCT04273282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexycu intracameral dexamethasone
Description: To evaluate the safety and ocular efficacy of Dexycu.
Study NCT04273282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
Study NCT00006111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00099359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Given for 6 weeks. 12mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW \< 2000 grams
Study NCT00099359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Description: Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW \< 2000 grams
Study NCT00099359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epivir (3TC)
Description: Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams
Study NCT00099359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Description: 200 mg BID if birth weight (BW) > 3000 grams for 2 weeks;150 mg BID if BW > 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
Study NCT01337531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-F, Fostimon
Description: dosage form
Study NCT01337531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F, Fostimon
Description: injection, daily, 10-15 days
Study NCT01144078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Intensity Exercise
Description: The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
Study NCT04675944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: 1 mg (1 extended-release tablet), oral route
Study NCT04593342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Cure Pro
Description: The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
Study NCT04593342 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
Study NCT02227459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 Injection
Study NCT01144078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
Study NCT03907514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FALE Application
Description: FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care.
Study NCT04913207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: method of device size selection
Description: device size selection based on 3D-CTA
Study NCT04913207 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: method of device size selection
Description: device size selection based on 3D-CTA
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-01
Description: 14 day dosing
Study NCT04374110 — intervention group
Intervention type: OTHER
Intervention: Clinical data
Description: Clinical characteristics from medical records
Study NCT04373200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
Study NCT04373200 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples collection
Description: Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
Study NCT04373200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva collection at Month 4 for 25 survivors COVID-19 patients
Study NCT04373200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection at Month 4 for 25 survivors COVID-19 patients
Study NCT02059447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment waiting period
Description: All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
Study NCT02059447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment waiting period
Description: All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
Study NCT02059447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Study NCT02059447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Study NCT02589821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study NCT02589821 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study NCT03719131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Receive standard of care nivolumab therapy
Study NCT03719131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Receive standard of care nivolumab therapy
Study NCT03719131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given IV or SC
Study NCT00006111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03719131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Receive standard of care ipilimumab therapy
Study NCT03719131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Receive standard of care ipilimumab therapy
Study NCT01205516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
Study NCT01205516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Release Morphine
Description: controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
Study NCT04101773 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RBL versus sutured mucopexy versus haemorrhoidectomy.
Description: All 3 interventions are part of Dutch usual care, and serve as each other's control.
Study NCT00006111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00843856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
Study NCT00843856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil
Description: tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
Study NCT03302546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental hemodialysis
Description: Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
Study NCT03302546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
Study NCT01500395 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid operation
Description: Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
Study NCT01521013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported self-care
Description: Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook.
Study NCT01521013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupported self-care
Description: Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
Study NCT02384577 — intervention group
Intervention type: DRUG
Intervention: Budesonide, Formoterol Fumarate Dihydrate
Study NCT00078572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
Study NCT00078572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
Study NCT00078572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016)
Description: Lapatinib 1250 mg orally once daily
Study NCT04305574 — intervention group
Intervention type: BEHAVIORAL
Intervention: Use of social media during COVID-19
Description: Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
Study NCT05565859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planetary Health Plate signage
Description: A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
Study NCT04020718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief telephone advice plus tailored text messages
Description: All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
Study NCT04020718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
Study NCT04020718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive telephone coaching
Description: Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
Study NCT02477670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study NCT02477670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00588302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril
Description: Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
Study NCT00369733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
Study NCT04298788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blue dishware
Description: blue dishware is used for plates and bowls